Peter Rothwell

Peter Rothwell
Competing Interests

Have you in the past five years accepted the following from an organisation that may in any way gain or lose financially from the publication of papers in the BMJ?

a) Reimbursement for attending a symposium?
Yes, but usually only if I am an invited speaker

b) A fee for speaking?
Yes, several times each year

c) A fee for organising education?
No

d) Funds for research?
Shire Pharmaceuticals- Research grant to study Fabry disease in the Oxford Vascular Study

e) Funds for a member of staff?
Yes, as above

f) Fees for consulting?

Sanofi  - Fees for occasional advisory boards

Shire Pharmaceuticals - Honorarium for a talk.

Boerhinger-Ingelheim  - Fees for occasional advisory boards

Jiho Vigorous Inc  - Honorarium for lecture

Servier Pharmaceuticals - Fees for membership of the Steering Committee of

the PERFORM trial.

Bayer Healthcare - Fees for membership of the Steering Committee of the

ARRIVE trial.

Bristol-Myers Squibb - Fees for membership of the OSCARE Steering Committee

Johnson & Johnson Pharmaceuticals & Bayer Healthcare  - Fees for membership

of the Rocket AF Trial Data Monitoring Committee

Astra-Zeneca -  Fee for talk and consultancy at the Thrombosis Quorum

Advisory Summit Meeting 2007

Biotronic Inc.  - Fees for membership of the IMPACT Study Executive Committee 
Have you in the past five years been employed by any organisation that may in any way gain or lose financially from the publication of papers in the BMJ?

a) Do you hold any stocks or shares in an organisation?
No

b) Do you have any other competing financial interests?
No

c) I have no competing interests



BMJ in the Media